Forget needles, fat-jab PILLS are here: Why they're cheaper, how much weight you could lose & the side effects revealed
NEW ERA Forget needles, fat-jab PILLS are here: Why they're cheaper, how much weight you could lose & the side effects revealed
Click to share on X/Twitter (Opens in new window)
Click to share on Facebook (Opens in new window)
EVERYONE'S talking about fat jabs - the 'miracle' injections trimming inches off waistlines, and helping turn the tide on the obesity epidemic.
But what if there was an even easier - and cheaper - way than Ozempic-like injections, Wegovy and Mounjaro?
4
Slimming tablets have been around for decades - but now scientists want to harness the new momentum in obesity medicine to bring them back with a bang
Credit: Getty
4
Rival company Eli Lilly, which makes Mounjaro (tirzepatide) announced the results of its pill orforglipron in April
Credit: Getty
Science sits still for no slimmer and already, the next big thing is looming large on the horizon - and it could be as simple as popping a pill.
Slimming tablets have been around for decades, but now scientists want to harness the new momentum in obesity medicine - and use the billions being made from the jabs - to bring pills back with a bang.
Professor Jason Halford, of the European Association for the Study of Obesity, tells Sun Health: 'I think pills will eventually replace injections.
'People don't particularly like them and they're a bit afraid of injecting themselves.
'You've got to have the device, the needle, the sharps bin, it's got to be refrigerated, there are all sorts of challenges.
'If you can move it all to a tablet you can increase acceptance and hopefully it will be cheaper and become more widely available.'
Professor Richard Donnelly, editor of the medical journal Diabetes, Obesity and Metabolism, and clinical adviser at online weight loss clinic Juniper, agrees.
'Thirty years ago weight loss tablets had a terrible reputation and nobody really wanted to prescribe them,' he adds.
'They had rare but severe side effects and weren't particularly effective.
'Now there is a whole flood of development and a lot to be optimistic about.
Weight Loss Jabs - Pros vs Cons
'There is a big hope that developing pills will improve accessibility and cost less.'
There are several pills in development - some stimulate the same hormones as jabs to make us feel full, while others mimic bariatric surgery.
The end goal is the same - to do what willpower alone fails to achieve and stop us eating so much.
While some are yet to even be trialled in humans, one has already been submitted for approval in the US, meaning they could be available before the end of the year.
4
There's even a weight loss pill in development that will emulate a gastric bypass
Credit: Getty
The most advanced pills being made are by the same companies behind the fat jabs.
Novo Nordisk, creator of Wegovy and Ozempic, has developed a tablet version of semaglutide, the active drug in those injections.
It applied for approval from the US Food and Drugs Administration last month.
Trials showed patients lost an average of 15 per cent of their bodyweight over 17 months on a 50mg daily dose, compared with eight per cent over 12 months on Wegovy.
Participants were three times more likely to achieve 'meaningful' weight loss when they were taking the pill, compared to those not taking the tablet.
Rival company Eli Lilly, which makes Mounjaro (tirzepatide) announced the results of its pill orforglipron in April.
The two drugs both work by stimulating GLP-1 hormones that make you feel full.
What are the other side effects of weight loss jabs?
Like any medication, weight loss jabs can have side effects.
Common side effects of injections such as Ozempic include:
Nausea: This is the most commonly reported side effect, especially when first starting the medication. It often decreases over time as your body adjusts.
Vomiting: Can occur, often in conjunction with nausea.
Diarrhea: Some people experience gastrointestinal upset.
Constipation: Some individuals may also experience constipation.
Stomach pain or discomfort: Some people may experience abdominal pain or discomfort.
Reduced appetite: This is often a desired effect for people using Ozempic for weight loss.
Indigestion: Can cause a feeling of bloating or discomfort after eating.
Serious side effects can also include:
Pancreatitis: In rare cases, Ozempic may increase the risk of inflammation of the pancreas, known as pancreatitis, which can cause severe stomach pain, nausea, and vomiting.
Kidney problems: There have been reports of kidney issues, including kidney failure, though this is uncommon.
Thyroid tumors: There's a potential increased risk of thyroid cancer, although this risk is based on animal studies. It is not confirmed in humans, but people with a history of thyroid cancer should avoid Ozempic.
Vision problems: Rapid changes in blood sugar levels may affect vision, and some people have reported blurry vision when taking Ozempic.
Hypoglycemia (low blood sugar): Especially if used with other medications like sulfonylureas or insulin.
Patients taking 36mg of orforglipron lost eight per cent of their bodyweight in 10 months, equating to 1st 2lbs from an average starting weight of 14st 3lbs – while participants taking a placebo lost just 3lbs.
It compares with 15 per cent weight loss in a year on Mounjaro.
Lilly said their pill 'could be readily manufactured and launched at scale for use around the world'.
But injections and pills have not been compared head-to-head yet.
Studies are ongoing and taking the science behind these game-changing jabs and applying it to tablets, does not guarantee success.
Pfizer abandoned the development of its drug lotiglipron in 2023 when a trial indicated potential liver damage as a side effect.
Drugs tend to be more easily absorbed by the body when they are injected directly into the bloodstream, compared to being digested through the gut.
And that's another key consideration - what the potential side effects of these new pills could be.
Unpleasant side effects were the downfall of the old generation of slimming pills.
4
Novo Nordisk, creator of Wegovy and Ozempic, has developed a tablet version of semaglutide, the active drug in those injections
Credit: Getty
The NHS has prescribed a pill called orlistat for years, dishing out £12million worth of it in England last year.
It works by preventing the gut from absorbing fat from food - but it means fat must be passed out in poo instead of digested.
This can lead to flatulence, more regular bowel movements and diarrhoea.
It can also cause bladder pains and breathing troubles - and weight loss doesn't match up to the jabs.
About eight in 10 patients suffer at least one side effect when using injections, most commonly tummy upset, according to trials.
Everything you need to know about fat jabs
Weight loss jabs are all the rage as studies and patient stories reveal they help people shed flab at almost unbelievable rates, as well as appearing to reduce the risk of serious diseases.
Wegovy – a modified version of type 2 diabetes drug Ozempic – and Mounjaro are the leading weight loss injections used in the UK.
Wegovy, real name semaglutide, has been used on the NHS for years while Mounjaro (tirzepatide) is a newer and more powerful addition to the market.
Mounjaro accounts for most private prescriptions for weight loss and is set to join Wegovy as an NHS staple this year.
How do they work?
The jabs work by suppressing your appetite, making you eat less so your body burns fat for energy instead and you lose weight.
They do this my mimicking a hormone called GLP-1, which signals to the brain when the stomach is full, so the drugs are officially called GLP-1 receptor agonists.
They slow down digestion and increase insulin production, lowering blood sugar, which is why they were first developed to treat type 2 diabetes in which patients' sugar levels are too high.
Can I get them?
NHS prescriptions of weight loss drugs, mainly Wegovy and an older version called Saxenda (chemical name liraglutide), are controlled through specialist weight loss clinics.
Typically a patient will have to have a body mass index (BMI) of 30 or higher, classifying them as medically obese, and also have a weight-related health condition such as high blood pressure.
GPs generally do not prescribe the drugs for weight loss.
Private prescribers offer the jabs, most commonly Mounjaro, to anyone who is obese (BMI of 30+) or overweight (BMI 25-30) with a weight-related health risk.
Private pharmacies have been rapped for handing them out too easily and video calls or face-to-face appointments are now mandatory to check a patient is being truthful about their size and health.
Are there any risks?
Yes – side effects are common but most are relatively mild.
Around half of people taking the drug experience gut issues, including sickness, bloating, acid reflux, constipation and diarrhoea.
Dr Sarah Jarvis, GP and clinical consultant at patient.info, said: 'One of the more uncommon side effects is severe acute pancreatitis, which is extremely painful and happens to one in 500 people.'
Other uncommon side effects include altered taste, kidney problems, allergic reactions, gallbladder problems and hypoglycemia.
Evidence has so far been inconclusive about whether the injections are damaging to patients' mental health.
Figures obtained by The Sun show that, up to January 2025, 85 patient deaths in the UK were suspected to be linked to the medicines.
Early data suggests pills might have similar rates.
Around six per cent of people taking any of Lilly or Novo Nordisk's pills or injections quit the medicines because of side effects.
Dr Leyla Hannbeck, of the Independent Pharmacies Association, says: 'The old generation drugs tended to be uncomfortable for a lot of people whereas these new ones are much more effective.
'All medicines will have side effects but the fact that the results are much better now means people are more willing to endure them.'
Prof Donnelly said he still does not expect new tablets to be as strong as jabs, adding: 'I don't think anybody believes these will cause the same level of weight loss that you might be reporting with Mounjaro.
'The flipside of that is that major weight loss might not all be good.
'Some of that might be muscle and if you lose 30 per cent of your body weight that is a fairly major transformation.
'Having an oral agent that reduces your weight by, say, 10 or 15 per cent, might actually be more sustainable, better tolerated and medically safer in some respects.'
While the GLP-1 tablets are likely to be first to market, inventors are also working on a daily pill that mimics the effects of gastric bypass surgery.
'GASTRIC BYPASS' PILL
US company Syntis Bio's offering, named Synt-101 creates a 24-hour lining in the gut that means food cannot be absorbed in the top six inches of the small intestine.
Rather, digestion is redirected to the lower areas of the gut, where hormones that tell the brain we are full, are triggered faster.
Working in a similar vein to surgery, it means patients feel fuller faster - and the lining is passed when the patient goes to the loo the next day.
Synt-101 has passed its first human safety tests and is expected to enter a full-scale clinical trial next year.
Another pill in development, Sirona, is made by UK-based Oxford Medical Products, and contains a 'dual polymer hydrogel' that expands in the stomach when it comes into contact with water.
It works like a gastric balloon, filling the patient's tummy making them feel full for hours, but is passed in their stools 'several days' later.
Early data from an NHS trial found patients lost 10 to 12 per cent in a year of treatment and there were no serious side effects.
Experts believe weight loss pills will serve a variety of purposes - as a follow-on treatment after stopping fat jabs, as an option for those who can't or don't want to use jabs and for people with less severe obesity, and less weight to lose.
There are hopes they will be less toxic than injections, which often cause side effects like stomach aches, vomiting or diarrhoea.
Weight regain after treatment is also an emerging issue with the jabs, which can currently only be prescribed for up to two years in the UK.
Rahul Dhanda, chief executive of Syntis Bio, said: 'Patients don't want to be stuck on a revolving door of injections and their side effects; they want to be on a manageable and sustainable weight loss path.
'Oral drugs that are simple, tolerable and safe will be the rational choice for maintenance therapy.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Times
43 minutes ago
- Times
Viking shares shed 40% of value after weight-loss pill setback
A biopharma company suffered a near 40 per cent slump in its share price after the results of its experimental weight-loss pill disappointed investors. Data from Viking Therapeutics, which is in a race with multinational pharma companies including Eli Lilly and Novo Nordisk to develop a next-generation oral treatment, showed its drug helped people with obesity lose up to 12.2 per cent of their body weight over 13 weeks, on the highest dose of the medication. Before the keenly awaited results, analysts expected Viking's drug, known as VK2735, to demonstrate weight loss of between 10 per cent and 15 per cent on average. However, shares in the San Diego-based company slumped by more than a third in New York after the data also showed that more patients stopped taking the treatment compared with those who received a placebo in the mid-stage study. Approximately 38 per cent of those taking the highest dose discontinued the medication early. Gastrointestinal side effects were the most common reasons. Novo Nordisk, the Danish company, and Eli Lilly, one of the world's biggest drugs companies, have dominated the initial weight-loss market through their breakthrough injectable treatments, Wegovy and Zepbound, respectively. They are among a pack of companies competing to develop oral therapies, which are deemed more appealing because of their easier dosing regimens. • Ozempic sales 'rise by 500%' after Mounjaro price hike announcement Analysts have estimated the weight-loss market could be worth up to $150 billion by the end of the decade, although shares in Eli Lilly and Novo have dropped in recent months, weighed down by Donald Trump's pharma industry tariff and price-cut threats, competition from copycat US drugs and mixed trial results for next-generation medicines. This month's data from Eli Lilly's experimental pill also disappointed investors, with patients losing an average of 12.4 per cent of their body weight, which was at the lower end of the market's expectations. Analysts also noted that the trial showed worse-than-expected side effects. Novo Nordisk has previously shown its oral weight-loss drug helped trial participants to lose about 15 per cent of their body weight and has been submitted for approval in the US, the world's most lucrative drugs market. Brian Lian, Viking's chief executive, said 'As in prior studies we observed a clear dose response and impressive weight loss across the 13-week treatment period. The progressive nature of the weight-loss curves suggests the potential for further improvement with longer dosing periods.' Viking shares were $17.66, or 42 per cent, lower at $24.43 by lunchtime in New York, valuing the company at $2.8 billion.
Times
an hour ago
- Times
Mounjaro UK price rise will trigger obesity relapse, say experts
The upcoming Mounjaro price hike could cause people to pile weight back on and 'cycle in and out of obesity', experts have warned. The weight-loss jab, which is bought privately by 1.5 million people in the UK, will more than double in price next month — forcing patients off the drug if they can no longer afford it. Its manufacturer, Eli Lilly, is increasing the list price for the maximum 15mg dose from £122 to £330 for a monthly pen, while the 5mg dose is rising from £92 to £180. Pharmacies have warned that patients are in 'immense distress', with demand soaring as they stock up on Mounjaro before the price increase takes effect on September 1. Professor Tim Spector, a nutrition expert at King's College London, warned that the sudden increase in price had exposed the flaws of relying on weight-loss jabs to lose weight. He said: 'The price rise of the GLP-1 drugs comes at a tricky time for the million-plus Britons that have started taking the drugs. Any losses in weight they will have achieved will be reversed in just a few weeks, as their appetite kicks back in. 'People are being prompted to use these private networks of GLP-1 drugs without any real supervision, and, crucially, without any nutritional support.' Spector, co-founder of the Zoe nutrition app, said that people who were taking weight-loss jabs should instead have been 're-educated about food and good eating habits long term'. He added: 'It's a huge wasted opportunity that's going to get worse as the price for the consumer goes up, and therefore people are unlikely to stay on this long term. We're just going to be back to good old short-term diets, which will cycle people in and out of obesity.' The price hike is taking place after President Trump demanded that pharmaceutical firms lower prices for American patients and stop other countries 'freeloading' off US firms. Pharmacies said they were experiencing record demand and were helping people to switch from Mounjaro to Wegovy, a similar GLP-1 drug known as Ozempic when used for diabetes, as it is cheaper, although not thought to be as effective. • Jon Yeomans: Mounjaro is a taste of the battle to come over drug prices James O'Loan, the chief executive of the online pharmacy Chemist4U, said: 'The distressing news that prices are set to rise by up to 170 per cent with just two weeks' notice, in response to another aggressive initiative from Trump, is very troubling. It's caused immense distress to hundreds of thousands of UK patients on a weight loss journey, who worry all their hard-earned progress could be snatched away from them.' Asda Online Doctor said: 'Following the announcement of steep price increases by the manufacturer Eli Lilly starting in September, we have seen an instant 350 per cent increase in demand. We are making all efforts to enable our existing patients to continue treatment and are actively prioritising them. 'However, this will be a difficult situation for many of our patients with affordability being a key aspect in the access and/or continuation of these services. Therefore we deeply regret this decision from Eli Lilly to increase prices, which will affect many patients. We remain committed to providing an excellent service to our patients at a fair price.' • Mounjaro transformed me — but it had a huge effect on my family's life Dr Leyla Hannbeck, chief executive of the Independent Pharmacies Association, representing thousands of community pharmacies, said: 'Our members up and down the country have been dealing with worried patients, many of whom are enquiring about stocking up before the price increase hits. 'There is a very real danger that the higher prices will see patients desperate for cheaper products turn to the, often unregulated, online market.' Sandeep Dhami, a superintendent pharmacist at MW Phillips Chemists in the West Midlands, added: 'Patients on their weight-loss journeys are coming into pharmacies like mine angry and upset at the news of the price hike. Those on the highest doses, who will face the highest price hike are particularly concerned.'
The Independent
4 hours ago
- The Independent
Half-off Ozempic? US patients paying in cash can now buy the popular weight-loss drug for less
American diabetes patients will now be able to buy the wildly popular weight-loss drug Ozempic for half its usual price — as long as they pay out of pocket. Danish pharmaceutical company Novo Nordisk said on Monday that it would make the drug available through its direct pharmacy service for $499 per month, compared to a list price of just under $1,000 per month. The drug is available as an obesity medication under the alternate brand name Wegovy but will now be sold to patients with diabetes prescriptions as well. Scientifically known as semaglutide, Ozempic and other GLP-1 agonists have rapidly transformed weight loss and diabetes treatment across the world, while at one point boosting Novo Nordisk's profits enough to raise the entire GDP of Denmark. It comes after President Donald Trump specifically called out GLP-1 agonists for being more expensive in the U.S. than in other countries, claiming he would "slash the cost of prescription drugs" by as much as 80 percent. He also accused European nations of "unfairly shifting the cost burden onto American patients" by using the bargaining power of their large single-payer healthcare services to force U.S. pharma companies to accept lower prices. Big Pharma has been responsive, with Pfizer CEO Albert Bourla recently admitting that he and other firms are discussing ways to make their drugs available more cheaply. Sales of Ozempic surged by 500 to 600 percent in the U.K. after its competitor Mounjaro announced that prices would more than triple starting on September 1. But Trump's tariffs could also raise the price of U.S. drugs that are manufactured abroad unless pharma companies or foreign governments can agree some exemption. Novo Nordisk launched its NovaCare pharmacy in March, offering Wegovy for $499 to patients willing to skip insurance and forego any reimbursement. More recently the president upgraded his promise on drug prices to say he would cut them by up to "1,500 percent", which is mathematically impossible without going into negative numbers. In Ozempic's case, reducing the list price by 1,500 percent would result in Novo Nordisk paying American patients around $14,000 for a month's supply of the drug — which is unlikely.
